Revelation Historical Balance Sheet

REVB Stock

USD 0.40 0.01 2.44%

Trend analysis of Revelation Biosciences balance sheet accounts such as Long Term Debt of 135.7 M, Net Receivables of 7 M, Good Will of 29.3 M or Short Term Investments of 449.1 K provides information on Revelation Biosciences' total assets, liabilities, and equity, which is the actual value of Revelation Biosciences to its prevalent stockholders. By breaking down trends over time using Revelation Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Revelation Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Revelation Biosciences is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

About Revelation Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Revelation Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Revelation Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Revelation Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Revelation currently owns. An asset can also be divided into two categories, current and non-current.

Revelation Biosciences Balance Sheet Chart

At present, Revelation Biosciences' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 38.8 M, whereas Total Assets are forecasted to decline to about 10.4 M.

Total Assets Accounts Payable Long Term Debt Net Receivables

Total Assets

Total assets refers to the total amount of Revelation Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Revelation Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Accounts Payable

An accounting item on the balance sheet that represents Revelation Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Revelation Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Long Term Debt

Long-term debt is a debt that Revelation Biosciences has held for over one year. Long-term debt appears on Revelation Biosciences balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Revelation Biosciences balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most accounts from Revelation Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Revelation Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.At present, Revelation Biosciences' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 38.8 M, whereas Total Assets are forecasted to decline to about 10.4 M.

	2022	2023	2024	2025 (projected)
Cash	5.3M	12.0M	10.8M	10.3M
Accounts Payable	554.2K	1.4M	1.2M	812.7K

Cash Accounts Payable

Revelation Biosciences balance sheet Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Long Term Investments	Intangible Assets	Total Current Liabilities	Other Liab	Net Tangible Assets	Other Assets	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt	Short Term Debt	Other Current Liab	Non Current Assets Total	Non Currrent Assets Other
Total Assets		0.99	0.91	-0.05	0.77	-0.93	-0.85	-0.53	0.82	1.0	-0.79	0.87	1.0	-0.83	0.71	0.79	0.8	-0.77	0.64	0.83	0.11	0.4	0.99	-0.72	-0.29	-0.29
Total Stockholder Equity	0.99		0.93	0.0	0.76	-0.93	-0.79	-0.5	0.81	0.99	-0.72	0.82	0.99	-0.81	0.71	0.78	0.79	-0.75	0.66	0.82	0.1	0.38	0.97	-0.7	-0.28	-0.28
Retained Earnings	0.91	0.93		0.14	0.78	-0.85	-0.63	-0.5	0.86	0.9	-0.55	0.64	0.89	-0.75	0.8	0.81	0.83	-0.83	0.77	0.84	0.27	0.43	0.84	-0.8	-0.11	-0.11
Accounts Payable	-0.05	0.0	0.14		0.36	0.13	0.28	0.17	0.32	-0.06	0.3	-0.24	-0.07	-0.15	0.42	0.31	0.3	-0.01	0.53	0.29	0.6	0.03	-0.11	-0.02	-0.1	-0.1
Cash	0.77	0.76	0.78	0.36		-0.7	-0.68	-0.53	0.97	0.77	-0.66	0.7	0.77	-0.91	0.98	0.98	0.98	-0.81	0.94	0.98	0.68	0.42	0.75	-0.78	-0.34	-0.33
Long Term Debt	-0.93	-0.93	-0.85	0.13	-0.7		0.86	0.51	-0.75	-0.93	0.77	-0.83	-0.93	0.84	-0.66	-0.73	-0.74	0.68	-0.59	-0.76	-0.09	-0.2	-0.92	0.63	0.28	0.28
Net Receivables	-0.85	-0.79	-0.63	0.28	-0.68	0.86		0.64	-0.68	-0.85	0.99	-0.99	-0.88	0.8	-0.58	-0.7	-0.71	0.72	-0.45	-0.73	-0.11	-0.33	-0.9	0.68	0.25	0.25
Good Will	-0.53	-0.5	-0.5	0.17	-0.53	0.51	0.64		-0.54	-0.53	0.7	-0.58	-0.54	0.48	-0.51	-0.55	-0.56	0.77	-0.43	-0.56	-0.26	-0.83	-0.53	0.76	-0.03	-0.03
Short Term Investments	0.82	0.81	0.86	0.32	0.97	-0.75	-0.68	-0.54		0.82	-0.64	0.69	0.81	-0.92	0.98	0.99	0.99	-0.85	0.95	1.0	0.66	0.45	0.78	-0.81	-0.33	-0.33
Total Liab	1.0	0.99	0.9	-0.06	0.77	-0.93	-0.85	-0.53	0.82		-0.79	0.88	1.0	-0.83	0.71	0.79	0.8	-0.77	0.63	0.83	0.11	0.4	0.99	-0.72	-0.29	-0.29
Long Term Investments	-0.79	-0.72	-0.55	0.3	-0.66	0.77	0.99	0.7	-0.64	-0.79		-0.97	-0.82	0.75	-0.55	-0.67	-0.68	0.72	-0.41	-0.69	-0.13	-0.41	-0.85	0.69	0.21	0.21
Intangible Assets	0.87	0.82	0.64	-0.24	0.7	-0.83	-0.99	-0.58	0.69	0.88	-0.97		0.9	-0.8	0.59	0.72	0.72	-0.72	0.46	0.74	0.1	0.35	0.93	-0.68	-0.27	-0.27
Total Current Liabilities	1.0	0.99	0.89	-0.07	0.77	-0.93	-0.88	-0.54	0.81	1.0	-0.82	0.9		-0.83	0.71	0.79	0.8	-0.78	0.63	0.83	0.11	0.4	0.99	-0.72	-0.29	-0.29
Other Liab	-0.83	-0.81	-0.75	-0.15	-0.91	0.84	0.8	0.48	-0.92	-0.83	0.75	-0.8	-0.83		-0.88	-0.93	-0.93	0.7	-0.83	-0.93	-0.52	-0.25	-0.83	0.65	0.56	0.56
Net Tangible Assets	0.71	0.71	0.8	0.42	0.98	-0.66	-0.58	-0.51	0.98	0.71	-0.55	0.59	0.71	-0.88		0.98	0.98	-0.82	0.98	0.98	0.76	0.44	0.67	-0.79	-0.29	-0.29
Other Assets	0.79	0.78	0.81	0.31	0.98	-0.73	-0.7	-0.55	0.99	0.79	-0.67	0.72	0.79	-0.93	0.98		1.0	-0.85	0.94	1.0	0.69	0.45	0.77	-0.81	-0.35	-0.35
Other Current Assets	0.8	0.79	0.83	0.3	0.98	-0.74	-0.71	-0.56	0.99	0.8	-0.68	0.72	0.8	-0.93	0.98	1.0		-0.86	0.94	1.0	0.68	0.46	0.78	-0.83	-0.34	-0.34
Other Stockholder Equity	-0.77	-0.75	-0.83	-0.01	-0.81	0.68	0.72	0.77	-0.85	-0.77	0.72	-0.72	-0.78	0.7	-0.82	-0.85	-0.86		-0.73	-0.86	-0.47	-0.7	-0.74	0.99	-0.06	-0.06
Total Current Assets	0.64	0.66	0.77	0.53	0.94	-0.59	-0.45	-0.43	0.95	0.63	-0.41	0.46	0.63	-0.83	0.98	0.94	0.94	-0.73		0.93	0.79	0.38	0.58	-0.7	-0.31	-0.31
Common Stock	0.83	0.82	0.84	0.29	0.98	-0.76	-0.73	-0.56	1.0	0.83	-0.69	0.74	0.83	-0.93	0.98	1.0	1.0	-0.86	0.93		0.64	0.46	0.81	-0.82	-0.33	-0.33
Property Plant Equipment	0.11	0.1	0.27	0.6	0.68	-0.09	-0.11	-0.26	0.66	0.11	-0.13	0.1	0.11	-0.52	0.76	0.69	0.68	-0.47	0.79	0.64		0.26	0.08	-0.47	-0.19	-0.19
Short Long Term Debt	0.4	0.38	0.43	0.03	0.42	-0.2	-0.33	-0.83	0.45	0.4	-0.41	0.35	0.4	-0.25	0.44	0.45	0.46	-0.7	0.38	0.46	0.26		0.38	-0.69	0.09	0.09
Short Term Debt	0.99	0.97	0.84	-0.11	0.75	-0.92	-0.9	-0.53	0.78	0.99	-0.85	0.93	0.99	-0.83	0.67	0.77	0.78	-0.74	0.58	0.81	0.08	0.38		-0.69	-0.32	-0.32
Other Current Liab	-0.72	-0.7	-0.8	-0.02	-0.78	0.63	0.68	0.76	-0.81	-0.72	0.69	-0.68	-0.72	0.65	-0.79	-0.81	-0.83	0.99	-0.7	-0.82	-0.47	-0.69	-0.69		-0.12	-0.12
Non Current Assets Total	-0.29	-0.28	-0.11	-0.1	-0.34	0.28	0.25	-0.03	-0.33	-0.29	0.21	-0.27	-0.29	0.56	-0.29	-0.35	-0.34	-0.06	-0.31	-0.33	-0.19	0.09	-0.32	-0.12		1.0
Non Currrent Assets Other	-0.29	-0.28	-0.11	-0.1	-0.33	0.28	0.25	-0.03	-0.33	-0.29	0.21	-0.27	-0.29	0.56	-0.29	-0.35	-0.34	-0.06	-0.31	-0.33	-0.19	0.09	-0.32	-0.12	1.0

Click cells to compare fundamentals

Revelation Biosciences Account Relationship Matchups

Revelation Biosciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	4.6M	2.0M	5.5M	12.2M	11.0M	10.4M
Total Stockholder Equity	3.4M	(99.5K)	1.1M	6.6M	6.0M	5.7M
Retained Earnings	(2.5M)	(14.5M)	(25.3M)	(25.5M)	(22.9M)	(21.8M)
Accounts Payable	865.9K	596.3K	554.2K	1.4M	1.2M	812.7K
Cash	4.5M	1.3M	5.3M	12.0M	10.8M	10.3M
Total Liab	1.2M	2.1M	4.5M	5.6M	5.0M	4.8M
Total Current Liabilities	1.2M	2.1M	4.5M	5.6M	5.0M	4.8M
Other Liab	5.9M	8.0M	76.4M	50.7M	58.3M	32.4M
Net Tangible Assets	234.4M	273.9M	3.0M	(7.8M)	(7.0M)	(6.7M)
Other Current Assets	128K	637.3K	73.1K	155.8K	140.2K	133.2K
Other Stockholder Equity	5.5M	14.4M	26.4M	32.1M	36.9M	38.8M
Total Current Assets	4.6M	1.9M	5.4M	12.1M	10.9M	10.4M
Common Stock	2.3K	2.3K	683.0	265.0	238.5	226.58
Other Current Liab	342.9K	1.5M	3.9M	4.2M	4.8M	5.1M
Non Current Assets Total	73.5M	130.1K	90.1K	65.1K	58.6K	55.6K
Liabilities And Stockholders Equity	4.6M	2.0M	5.5M	12.2M	14.0M	14.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:

How To Invest In Revelation

Details

Is Revelation Stock a good investment?

Details

What is Revelation Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(16.93)

Return On Assets

(0.51)

Return On Equity

(2.70)

The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Revelation Historical Balance Sheet

About Revelation Balance Sheet Analysis

Revelation Biosciences Balance Sheet Chart

Total Assets

Accounts Payable

Long Term Debt

Revelation Biosciences balance sheet Correlations

Revelation Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Revelation Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Total Assets
Common Stock	+ 1.0	Short Term Investments
Total Current Liabilities	+ 1.0	Total Liab
Other Current Assets	+ 1.0	Other Assets
Common Stock	+ 1.0	Other Assets

Intangible Assets	- 0.99	Net Receivables
Intangible Assets	- 0.97	Long Term Investments
Common Stock	- 0.93	Other Liab
Other Current Assets	- 0.93	Other Liab
Other Assets	- 0.93	Other Liab
Total Current Liabilities	- 0.93	Long Term Debt